← Back to Search

PET Scan with DPA-714 for Parkinson's Disease

Phase 1 & 2
Recruiting
Led By Jonathan McConathy, MD
Research Sponsored by University of Alabama at Birmingham
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
No Placebo-Only Group

Summary

This trial will measure the level of neuroinflammation in the brains of people with Parkinson's disease compared to healthy controls, using a PET scan with the tracer [18F]DPA-714.

Who is the study for?
This trial is for participants already enrolled in the UAB Neuroinflammation in Parkinson's Disease study. It's specifically for those who can undergo PET/MRI scans and are not pregnant or at risk of pregnancy. Individuals must have a certain genetic profile (high or mixed affinity binder) that allows them to bind well with the imaging agent used.
What is being tested?
The substudy is testing how a PET tracer called [18F]DPA-714 distributes and concentrates in the brain, which could indicate levels of neuroinflammation in Parkinson’s patients compared to healthy individuals. The tracer binds to proteins associated with inflammation in brain immune cells.
What are the potential side effects?
While specific side effects are not listed, typical risks may include reactions to the PET tracer, discomfort from lying still during imaging, and potential issues related to MRI such as claustrophobia or reactions to contrast agents if used.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Comparison of TSPO-PET measures of neuroinflammation between PD patients and healthy controls.
Correlation of DPA-714-PET/MRI with demographics, clinical and biospecimen assessments from Neuroinflammation in PD study

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

4Treatment groups
Experimental Treatment
Group I: UDALL 5-year Follow-up CohortExperimental Treatment1 Intervention
n-67 from baseline early Parkinson's disease cohort
Group II: Metabolite Analysis CohortExperimental Treatment1 Intervention
n-5 from baseline early Parkinson's disease cohort
Group III: Baseline Cohort Healthy Controls, DPA-714-PET/MRIExperimental Treatment1 Intervention
n-105
Group IV: Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRIExperimental Treatment1 Intervention
n-100

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

University of Alabama at BirminghamLead Sponsor
1,655 Previous Clinical Trials
2,443,603 Total Patients Enrolled
Jonathan McConathy, MDPrincipal InvestigatorUniversity of Alabama at Birmingham
2 Previous Clinical Trials
180 Total Patients Enrolled

Media Library

DPA-714-PET/MRI Clinical Trial Eligibility Overview. Trial Name: NCT03457493 — Phase 1 & 2
Parkinson's Disease Research Study Groups: Baseline Cohort Healthy Controls, DPA-714-PET/MRI, Metabolite Analysis Cohort, Baseline Cohort Early Parkinson's Disease, DPA-714-PET/MRI, UDALL 5-year Follow-up Cohort
Parkinson's Disease Clinical Trial 2023: DPA-714-PET/MRI Highlights & Side Effects. Trial Name: NCT03457493 — Phase 1 & 2
DPA-714-PET/MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03457493 — Phase 1 & 2
~54 spots leftby Jun 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top